The Impact of Once Daily Dosing on Protein Binding of Clozapine and Norclozapine.

IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Journal of Clinical Psychopharmacology Pub Date : 2025-05-01 Epub Date: 2025-03-11 DOI:10.1097/JCP.0000000000001979
Marieke M Beex-Oosterhuis, S F Cedric Lau, Charlotte van Kesteren, Steven Verloop, Koen P Grootens, Gunnar Faber, Arthur R Van Gool, E R Rob Heerdink, Rob J van Marum, Daan J Touw
{"title":"The Impact of Once Daily Dosing on Protein Binding of Clozapine and Norclozapine.","authors":"Marieke M Beex-Oosterhuis, S F Cedric Lau, Charlotte van Kesteren, Steven Verloop, Koen P Grootens, Gunnar Faber, Arthur R Van Gool, E R Rob Heerdink, Rob J van Marum, Daan J Touw","doi":"10.1097/JCP.0000000000001979","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose/background: </strong>Clozapine and norclozapine are highly protein bound. Currently, clozapine is increasingly prescribed once daily (QD). Higher (once daily) doses may theoretically lead to saturation of protein binding of (nor)clozapine, resulting in increased unbound fractions. This study investigated whether protein binding of clozapine and norclozapine becomes saturated at higher concentrations. Secondly, the correlation between unbound (nor)clozapine fractions and alpha-1 acid glycoprotein (AGP) concentrations was studied.</p><p><strong>Methods/procedures: </strong>From 44 patients taking clozapine QD or twice daily a total of 319 blood samples were collected at different time points within a dose interval. AGP concentrations were measured in samples drawn just before clozapine intake. A validated liquid chromatography-tandem mass spectrometry method was used for quantification of the (nor)clozapine concentrations. Ultrafiltration was used to separate the bound and unbound molecules. The relation between total concentrations and fractions, and between unbound fractions and AGP concentrations were investigated using linear mixed model analysis.</p><p><strong>Findings/results: </strong>There was no significant correlation between total clozapine ( P = 0.270) and norclozapine ( P = 0.678) concentrations and its unbound fractions with total clozapine concentrations up to 1500 μg/L. A statistically significant (negative) correlation between AGP concentrations and clozapine ( P = 0.000) and norclozapine ( P = 0.028) unbound fractions was found.</p><p><strong>Implications/conclusions: </strong>In general, total concentrations remain suitable for therapeutic drug monitoring if clozapine is used once daily. Future research is needed to define if higher total concentrations are warranted in case of lower unbound fractions due to increased AGP concentrations.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":"231-235"},"PeriodicalIF":2.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JCP.0000000000001979","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose/background: Clozapine and norclozapine are highly protein bound. Currently, clozapine is increasingly prescribed once daily (QD). Higher (once daily) doses may theoretically lead to saturation of protein binding of (nor)clozapine, resulting in increased unbound fractions. This study investigated whether protein binding of clozapine and norclozapine becomes saturated at higher concentrations. Secondly, the correlation between unbound (nor)clozapine fractions and alpha-1 acid glycoprotein (AGP) concentrations was studied.

Methods/procedures: From 44 patients taking clozapine QD or twice daily a total of 319 blood samples were collected at different time points within a dose interval. AGP concentrations were measured in samples drawn just before clozapine intake. A validated liquid chromatography-tandem mass spectrometry method was used for quantification of the (nor)clozapine concentrations. Ultrafiltration was used to separate the bound and unbound molecules. The relation between total concentrations and fractions, and between unbound fractions and AGP concentrations were investigated using linear mixed model analysis.

Findings/results: There was no significant correlation between total clozapine ( P = 0.270) and norclozapine ( P = 0.678) concentrations and its unbound fractions with total clozapine concentrations up to 1500 μg/L. A statistically significant (negative) correlation between AGP concentrations and clozapine ( P = 0.000) and norclozapine ( P = 0.028) unbound fractions was found.

Implications/conclusions: In general, total concentrations remain suitable for therapeutic drug monitoring if clozapine is used once daily. Future research is needed to define if higher total concentrations are warranted in case of lower unbound fractions due to increased AGP concentrations.

每日一次给药对氯氮平和去氯氮平蛋白结合的影响。
目的/背景:氯氮平和去氯氮平是高度蛋白结合的。目前,氯氮平越来越多地每天开一次(QD)。较高的剂量(每日一次)理论上可能导致(非)氯氮平的蛋白质结合饱和,导致未结合部分增加。本研究探讨了氯氮平和去氯氮平的蛋白结合是否在较高浓度下达到饱和状态。其次,研究了未结合(非)氯氮平组分与α -1酸性糖蛋白(AGP)浓度的相关性。方法/程序:对44例每日1次或每日2次服用氯氮平的患者,在同一剂量间隔内的不同时间点采集319份血样。在摄入氯氮平之前提取的样品中测量AGP浓度。采用经验证的液相色谱-串联质谱法定量测定氯氮平的浓度。用超滤分离结合和未结合的分子。采用线性混合模型分析研究了总浓度与组分、未结合组分与AGP浓度之间的关系。结果:总氯氮平浓度(P = 0.270)与去氯氮平浓度(P = 0.678)及其非结合组分与总氯氮平浓度在1500 μg/L以内无显著相关性。AGP浓度与氯氮平(P = 0.000)和去氯氮平(P = 0.028)未结合部分呈统计学显著(负)相关。意义/结论:总的来说,如果每天使用一次氯氮平,总浓度仍然适合用于治疗性药物监测。未来的研究需要确定,如果由于AGP浓度增加而导致未结合馏分降低,是否需要更高的总浓度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.00
自引率
3.40%
发文量
231
审稿时长
4-8 weeks
期刊介绍: Journal of Clinical Psychopharmacology, a leading publication in psychopharmacology, offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信